

Gait speed and handgrip strength as predictors of all-cause mortality and cardiovascular events in hemodialysis patient

Yu Ho Lee

CHA Bundang Medical Center

Jin Sug Kim

Kyung Hee University School of Medicine

Su Woong Jung

Kyung Hee University School of Medicine

Hyeon Seok Hwang

Kyung Hee University School of Medicine

Ju-Young Moon

Kyung Hee University School of Medicine

Kyung-Hwan Jeong

Kyung Hee University School of Medicine

Sang-Ho Lee

Kyung Hee University School of Medicine

So-Young Lee

Kyung Hee University School of Medicine

Gang Jee Ko

Korea University

Dong-Young Lee

Veterans Health Service medical center

Hong joo Lee

Seoul Red Cross Hospital

Yang Gyun Kim (✉ apple8840@hanmail.net)

Kyung Hee University School of Medicine <https://orcid.org/0000-0002-3497-5514>

Research article

Keywords: gait speed; handgrip strength; physical performance; hemodialysis; mortality

Posted Date: April 27th, 2020

DOI: <https://doi.org/10.21203/rs.2.21802/v3>

License:  This work is licensed under a Creative Commons Attribution 4.0 International License.

[Read Full License](#)

Version of Record: A version of this preprint was published at BMC Nephrology on May 6th, 2020. See the published version at <https://doi.org/10.1186/s12882-020-01831-8>.

Abstract

Background Low physical performance in patients undergoing maintenance hemodialysis is associated with a high mortality rate. We investigated the clinical relevance of gait speed and handgrip strength, the two most commonly used methods of assessing physical performance.

Methods We obtained data regarding gait speed and handgrip strength from 277 hemodialysis patients and evaluated their relationships with baseline parameters, mental health, plasma inflammatory markers, and major adverse clinical outcomes. Low physical performance was defined by the recommendations suggested by the Asian Working Group on Sarcopenia.

Results The prevalence of low gait speed and handgrip strength was 28.2% and 44.8%, respectively. Old age, low serum albumin levels, high comorbidity index score, and impaired cognitive functions were associated with low physical performance. Patients with isolated low gait speed exhibited a general trend for worse quality of life than those with isolated low handgrip strength. Gait speed and handgrip strength showed very weak correlations with different determining factors (older age, the presence of diabetes, and lower serum albumin level for low gait speed, and lower body mass index and the presence of previous cardiovascular events for low handgrip strength). Patients with low gait speed and handgrip strength had elevated levels of plasma endocan and matrix metalloproteinase-7 and the highest risks for all-cause mortality and cardiovascular events among the groups (adjusted hazard ratio of 2.72, $p = 0.024$). Elderly patients with low gait speed and handgrip strength were at the highest risk for poor clinical outcomes.

Conclusion Gait speed and handgrip strength reflected distinctive aspects of patient characteristics and the use of both factors improved the prediction of adverse clinical outcomes in hemodialysis patients. Gait speed seems to be a better indicator of poor patient outcomes than is handgrip strength.

Background

The increasing prevalence of end-stage renal disease (ESRD) is a major public health problem in most developed countries, including South Korea [1, 2]. Despite remarkable advances in dialysis modality and patient care, the mortality rate of ESRD patients is still exceedingly high compared with that of the general population [3]. Well-established risk factors for major adverse events associated with ESRD include old age, preexisting cardiovascular disease, the presence of diabetes, and underdialysis [4-10]. Nonetheless, hemodialysis patients exhibit high interindividual variability, and it is frequently difficult to predict the clinical course accurately on an individual level. The identification and management of potential risk factors is of particular importance because individualized therapeutic interventions might improve the clinical outcomes of ESRD patients.

Sarcopenia is defined as quantitative and qualitative loss of skeletal muscle that is frequently linked to adverse effects in patients [11]. Uremic toxins in chronic kidney disease (CKD) patients are often associated with not only the chronic catabolic state of inflammation, oxidative stress, and nutritional

imbalance but also a high prevalence of cardiovascular events, all of which eventually lead to clinically evident sarcopenia. Recent studies have highlighted that reduced physical performance is independently associated with poor patient survival and poor quality of life among CKD patients [12, 13], indicating the importance of physical activity in risk stratification among these patients. Currently, however, the optimal method of assessing physical performance in these populations has not yet been defined.

Measurements of gait speed (GS) and handgrip strength (HS) are used as reliable tests to determine the functioning of skeletal muscle [14, 15]. Both tests are simple, rapid, inexpensive, and can be performed in the geriatric population [16]. Accumulating evidence suggests that these parameters are useful for predicting outcomes in CKD [17-19] and ESRD patients [20-24]. Nonetheless, both tests have several limitations, such as a nonstandardized protocol or intraindividual variability. Moreover, performing either test may result in the misinterpretation of the performance status because dialysis patients frequently exhibit isolated problems in their upper or lower extremities but not the other parts of their body. Therefore, it can be speculated that combining these two simple tests may compensate for the shortcomings of each individual test. The aim of this study was to determine whether GS and HS have distinctive clinical relevance and whether combining these tests could offer a better indicator of patient outcomes than performing a single test.

Methods

Participant and study design

This study was performed using the data obtained from the K-cohort, a prospective cohort of 460 hemodialysis patients who visited six hospitals between June 2016 and January 2018 (CRIS no. KCT0003281). Inclusion/exclusion criteria was described previously [25]. The patient recruitment strategy is illustrated in **Figure 1**. In brief, after excluding 68 patients who were unable to be assessed for their physical performance because of their medical conditions and 115 patients who refused the tests, a total of 277 patients were finally enrolled in this study. We subsequently classified the enrolled patients into 4 groups based on their physical performance: normal GS and HS (n=119, 43.0%), normal GS and low HS (n=80, 28.9%), low GS and normal HS (n=34, 12.3%), and low GS and HS (n=44, 15.9%). Baseline demographics and clinical parameters, including the Charlson [26] and Liu [27] comorbidity indexes, were obtained at the time of study entry. All patients were monitored for major adverse events, which were defined as all-cause mortality and cardiovascular events, including acute coronary syndrome, symptomatic heart failure, cerebral infarction and hemorrhage, and peripheral artery disease, until June 2019.

Measurements of gait speed and handgrip strength

GS was measured after the end of a dialysis session on a treatment day with a short interdialytic interval (i.e., one-day interval) within one month of patient enrollment. We assessed GS by measuring the walking speed over a 4-m course at the participant's usual pace. The test was repeated three times, and the average speed was calculated. HS was measured by a Jamar hand dynamometer (Sammons Preston

Inc., Bolingbrook, IL) on the dominant hand unless contraindicated during dialysis sessions. Each measurement was repeated three times, and the highest value was noted. Based on the suggestions made by the Asian Working Group for Sarcopenia [28], low GS was defined as less than 0.8 m/s, and low HS was defined as less than 26 kg for men and less than 18 kg for women.

Questionnaires related to physical performance and mental health

Patients were asked to complete three questionnaires at the time of initial enrollment: the Korean version of the Mini-Mental Status Examination (K-MMSE) [29], the Beck Depression Inventory (BDI) [30], and the Korean version of the Kidney Disease Quality Of Life-Short Form (KDQOL-SF) [31]. We specifically obtained information regarding 11 ESRD-targeted domains on the KDQOL-SF, and these data were subsequently categorized into three components: physical, mental, and social. The physical components included the domains of physical functioning, pain, general health, and energy/fatigue. The mental components included the domains of cognitive function, sleep, and emotional well-being. Finally, the social components included work status, quality of social interaction, social support, and social function.

Measurement of plasma inflammatory markers

Plasma samples were collected before the initiation of dialysis and stored at -80°C until analysis. Multiple plasma inflammatory markers were simultaneously measured by multiplex enzyme-linked immunosorbent assay as previously described [32]. We reviewed the previous literature and selected the following candidate inflammatory markers: a proliferation-inducing ligand (APRIL), B-cell activating factor (BAFF), CXCL16, endocan, endostatin, follistatin, IL-6, IL-25, IL-18, monocyte chemoattractant protein-1 (MCP-1), MCP-2, MCP-4, matrix metalloproteinase-7 (MMP-7), MMP-8, osteoprotegerin, PCSK9, receptor activator of nuclear factor- κ B ligand (RANKL), and tumor necrosis factor- α (TNF- α).

Statistical analysis

All statistical analyses were performed with SPSS for Windows, version 20.0 (SPSS, Chicago, IL). Baseline characteristics and clinical parameters are expressed as the means \pm standard deviations (SDs) or as the numbers of patients and percentages. Analysis of variance (ANOVA) with Bonferroni post hoc analysis, chi-square test, and Fisher's exact test were used to compare these variables, as appropriate. Non-normally distributed variables, physical performance scores, comorbidity index, and quality of life scores were described as median [first and third interquartile range] and compared among the subgroups by the Kruskal–Wallis test with Bonferroni post hoc analysis. We used Pearson's correlation analyses to determine the relationship between GS and HS. Multiple logistic regression analysis was used to determine the risk factors for low GS and HS. Levels of plasma inflammatory markers were expressed as box-and-whisker plots, and their comparisons were made by ANOVA with Bonferroni post hoc analysis. Finally, Kaplan-Meier curves were generated to assess the probabilities of the patient outcomes according to GS and HS, and the Cox proportional hazards model was used for further multivariate adjustments with possible confounders including age, sex, previous history of cardiovascular disease, serum albumin

levels, and Charlson comorbidity index. *P* values less than 0.05 were considered to indicate statistical significance.

Result

Baseline clinical characteristics of patients

The baseline demographics and laboratory parameters of patients stratified by physical performance status are shown in **Table 1**. The prevalence of low GS and HS was 78 (28.2%) and 124 (44.8%), respectively. Patients with low GS and HS were older and had a lower body mass index and a shorter duration of dialysis than those in the other groups. The prevalence of previous cardiovascular events and diabetes was also higher in these patients. The predialysis serum albumin and creatinine levels were significantly lower in patients with poor physical performance, while spKt/V was inversely correlated with GS and HS. Mid-arm muscle circumference (MAMC) was positively correlated with GS and HS, although the statistical significance was marginal. Finally, a higher rate of the prescription of statins was observed in patients with low GS than in those with normal GS.

Associations among physical performance, comorbidity index scores, and mental health

We performed a correlation analysis to determine the relationship between GS and HS and found that the two parameters were significantly correlated with each other, but the correlation was weak ($R^2 = 0.070$ and $p < 0.001$; **Figure 2**). We next evaluated the relationships among physical performance, comorbidity index scores, and mental health. As shown in **Table 2**, GS and HS were significantly associated with comorbidity scores and poor physical status (Charlson comorbidity scores of 4 [2, 4] vs. 4 [3, 5] vs. 5 [3, 5] vs. 5 [4, 5] and Liu comorbidity scores of 4 [3, 5] vs. 4 [3, 6] vs. 6 [4, 7] vs. 6 [4, 7] for the normal GS and HS, normal GS and low HS, low GS and normal HS, and low GS and HS groups, respectively; $p < 0.001$ for both comparisons). In addition, patients with low GS and HS showed profoundly impaired cognitive functioning as assessed by the MMSE and the KDQOL-SF (28 [26, 29] vs. 27 [24, 28] vs. 27 [25, 30] vs. 27 [23, 29] and 87 [80, 100] vs. 87 [67, 100] vs. 80 [60, 93] vs. 73 [60, 93], normal GS and HS vs. normal GS and low HS vs. low GS and normal HS vs. low GS and HS groups; $p = 0.030$ and 0.007 , respectively). The social activity index was relatively maintained in the low GS and HS groups. Notably, the comorbidity scores, depression index scores, and quality of life scores were generally worse in patients with low GS and normal HS compared to those with normal GS and low HS, although statistical significance was only observed for the physical functioning status.

Risk factors for low gait speed and poor handgrip strength

Logistic regression analysis was performed to identify the determining factors of poor physical performance (**Table 3**). Older age was the only common risk factor for both low GS (adjusted odds ratio [OR] of 1.51, 95% confidence interval [CI] of 1.20 – 1.91; $p < 0.001$) and low HS (adjusted OR of 1.30, 95% CI of 1.07 – 1.57; $p = 0.008$). The presence of diabetes and low serum albumin levels were risk factors for low GS (adjusted OR of 2.12, 95% CI of 1.16 – 43.86 and adjusted OR of 3.37, 95% CI of 1.32 – 8.62,

respectively) but not for low HS. On the other hand, low HS but not low GS was significantly associated with low BMI (adjusted OR of 0.92, 95% CI of 0.86 – 0.99; $p = 0.022$) and a previous history of cardiovascular events (adjusted OR of 1.73, 95% CI of 1.02 – 2.95; $p = 0.043$).

The relationship between plasma inflammatory markers and physical performance

We next measured various plasma inflammatory markers and compared their levels across the groups. Among the cytokines and chemokines, the levels of plasma endocan and MMP-7 were significantly higher in patients with low GS and HS than in those with normal GS and HS (**Figure 3A and B**). In contrast, the levels of traditional inflammatory markers, including TNF- α , IL-6, and high sensitivity C-reactive protein (hs-CRP), were not associated with physical performance (**Figure 3C-E**).

Impacts of gait speed and handgrip strength on all-cause mortality and cardiovascular events

The mean duration of follow-up since the recruitment of patients was 25.3 months, and a total of 19 deaths (6.9%) and 30 (10.8%) cardiovascular events occurred during this period. Patients with low GS and HS showed the highest cumulative incidence rate for major adverse events (11.8%, 15.0%, 17.6%, and 29.5% for the normal GS and HS, normal GS and low HS, low GS and normal HS, and low GS and HS groups, respectively, $p = 0.004$ for overall comparisons; **Figure 4**).

The observed hazard ratios (HRs) for major adverse events are shown in **Table 4**. Multivariate Cox regression analysis revealed that patients with low GS and HS had the highest level of risk for major adverse events (adjusted HR of 2.72, 95% CI of 1.14 – 6.46; $p = 0.024$) compared to the risk levels of those with normal GS and HS after multivariate adjustments of possible confounders. Patients with normal HS but low GS also exhibited a tendency toward an increase in major adverse events (adjusted HR of 2.38, 95% CI of 0.86 – 6.53; $p = 0.084$). In contrast, isolated low HS was not related to an increased risk of adverse outcomes, although the adjusted HRs were slightly elevated. Notably, low GS and HS was associated with significantly increased composite event rate even after adjustment with patient' comorbidity scores (adjusted HR of 2.30, 95% CI of 1.02 – 5.21; $p = 0.045$). There was a significant interaction between GS and HS for major adverse events ($p = 0.019$). Finally, we performed a subgroup analysis of enrolled patients according to their age. As shown in **Figure 5**, physical performance was not associated with composite outcomes in hemodialysis patients under 65 years of age. In contrast, the risk of major adverse events was significantly increased in elderly patients with low GS and HS (adjusted HR of 5.76, 95% CI of 1.78 – 18.62; $p = 0.012$).

Discussion

Although sarcopenia was originally described as an age-related structural and functional decline in skeletal muscle, recent investigations have consistently acknowledged that decreased kidney function is also involved in sustained muscle wasting and the subsequent development of sarcopenia. Compared to the elderly population, in which the prevalence of sarcopenia is 11% [33], CKD patients are likely to be much more prone to its occurrence, with an estimated prevalence of 30 - 60% [20, 21, 24, 34-36]. The two

main components of sarcopenia, muscle strength and mass, are dissociated in the setting of ESRD, and the muscle strength is more important than muscle mass in terms of patient outcomes [20, 35]. In line with these findings, a recent meta-analysis showed a strong association between CKD progression and slowing of walking speed [37]. In this context, we extensively investigated the effects of skeletal muscle dysfunction on major adverse events in hemodialysis patients. Our findings suggest that GS and HS represent different aspects of patient characteristics and that their combination could identify those at the highest risk for mortality and cardiovascular events. Of note, MAMC showed a tendency to be relatively lower in patients with poor physical performance but was not related to either clinical outcome (data not shown). Together, our data support the idea that the functional assessment of skeletal muscle is more important than its quantitative assessment and that measuring GS and HS is a suitable method for the evaluation of skeletal muscle function in hemodialysis patients.

Based on the significant correlation between poor physical performance and high mortality in CKD patients, several prospective trials and meta-analysis have assessed whether exercise intervention could improve patient outcomes [38-45]. Although physical training significantly improved patient quality of life and inflammatory parameters in most studies, these benefits were not translated into better patient survival. One of the reasons for this discrepancy might be that patients enrolled in these studies were highly heterogeneous in their baseline clinical characteristics, underlying comorbidities, and laboratory findings. Moreover, there is no consensus on the definition of adequate exercise for hemodialysis patients, thereby limiting the application of intradialytic exercise in routine clinical practice. Therefore, well-designed randomized controlled trials are needed to clarify the clinical significance of intradialytic exercise, especially in terms of improving patient mortality.

We noticed that $spKt/V$, currently used as a standard method for the assessment of dialysis adequacy, was highest in patients with low GS and HS and lowest in patients with normal GS and HS (**Table 1**). The inverse relationship between Kt/V and physical performance was consistently shown in other studies, suggesting that this relationship is likely to be a universal phenomenon [24, 34, 36, 46]. We speculate that the low muscle mass and subsequent decreased volume of distribution of urea in the body (V) in patients with low GS and HS resulted in a relative increase in the value of Kt/V without affecting the true dialysis efficacy [47]. Therefore, sarcopenic patients may be underdialyzed if their dialysis time and dialyzer filter are selected solely based on the levels of Kt/V . Further study is warranted to define the optimal target of Kt/V in dialysis patients based on the severity of sarcopenia.

Although GS and HS are the two representative tests used to assess physical performance, direct comparisons of these parameters have rarely been made, especially in dialysis patients. Here, we examined their relationship and found that a substantial portion of patients exhibited low performance on one test while demonstrating normal performance on the other (114/277, 41.2%). Moreover, the correlation coefficient between GS and HS was very weak despite its statistical significance, suggesting that the factors contributing to these two conditions might be different. We consider that this finding is at least in part due to the differences in the muscles and neurologic systems involved during the execution of the HS and GS tests. In accordance with our data, Roshanravan *et al.* showed a discrepancy in upper

and lower muscle strength in a nondialysis CKD cohort study [19]. Thus, these data provide a rationale that the combination of the GS and HS tests could integrate the different patient components, thereby allowing us to predict future outcomes better.

Despite the fact that the clinical relevance of GS and HS as predictors of mortality and cardiovascular outcomes was documented in previous studies, direct comparisons between these two tests have not been performed so far. Interestingly, patients with isolated low GS had a tendency to exhibit worse comorbidity indexes and physical functions than those with isolated low HS (**Table 2**). Furthermore, GS was significantly superior than HS for the prediction of all-cause mortality in the analysis of our cohort, implying that the muscle function of the lower extremities might be more important than that of the upper extremities in terms of patient outcomes. Several recent studies also revealed that skeletal muscle function in the lower extremities but not in the upper extremities was associated with overall physical performance and the hospitalization rate [48, 49], emphasizing the clinical importance of lower extremity performance. Moreover, the GS test is still valuable because low GS is associated with increased HRs for death and cardiovascular mortality regardless of HS (**Figure 3 and Table 4**). Johansen et al. investigated longitudinal trends in the physical performance of hemodialysis patients and found that GS frequently declined while HS did not change over time [50]. GS was the strongest individual predictor of future frailty and mortality among various physical activity assessment tools, including HS, which is in line with our findings. Therefore, we consider that monitoring gait functions has the potential to serve as a valuable tool for continuous risk stratification of dialysis patients.

We found that the levels of endocan and MMP-7 were elevated in patients with low GS and HS. Endocan is a water-soluble proteoglycan consisting of amino acid polymers and a single dermatan sulfate chain [51]. Plasma endocan is known to exclusively originate from the vascular endothelium, and its levels reflect endothelial activation and systemic inflammation. Several previous studies have demonstrated the clinical value of plasma endocan in the prediction of cardiovascular mortality as well as the progression of kidney diseases [52-55]. It should be confirmed whether elevated levels of plasma endocan result from sarcopenia itself or from other confounding factors, such as vascular injuries or infection [56, 57]. MMP-7 is an endopeptidase that belongs to the MMP family. In addition to its basic functions in cleaving extracellular matrix substrates, MMP-7 is also involved in the development of local and systemic inflammation [58-60]. Although MMP-2 and MMP-9 seem to play major roles in the degradation of the extracellular matrix that leads to muscle wasting, the pathophysiological relevance of MMP-7 in the development and progression of sarcopenia is still mostly unknown. Increased MMP-7 activity is observed in a hereditary form of muscular dystrophy [61], suggesting that upregulated MMP-7 might have detrimental effects on skeletal muscle. In contrast with a previous report [20], the levels of hs-CRP, IL-6, and TNF- α were not elevated in sarcopenic patients in our study. We speculate that these inconsistent findings are attributable to the differences in the degree of overall inflammation; the absolute concentrations of hs-CRP and IL-6 were lower and the levels of serum albumin were higher in patients in our study than in those in the previous study [20].

Although low GS or HS alone was not predictive of patient outcomes in our cohort (**Table 4**), several other studies showed that isolated low GS or low HS was an independent predictor of all-cause mortality in patients with CKD [19-22]. This discrepancy is, at least in part, because the number of cardiovascular events in this study during follow-up was low. Thus, the statistical power of multivariable analysis with respect to separately analyzing the prognostic impacts of GS and HS was reduced. Moreover, the appropriate cutoff values for low GS and HS are still controversial, even though guidelines had already been established for Asian populations [28]. More vigorous validations are needed to determine the clinical relevance of these criteria as predictors of patient outcomes.

The limitations of this study should be mentioned. There is a concern about selection bias because patients who were incapable of performing the GS and/or HS tests were excluded from our study. Indeed, a previous study reported that dialysis patients who could not complete a walking test had the highest comorbidity index and worst survival rate, even when compared to those who could walk very slowly (< 0.6 m/s) [21]. Plasma inflammatory markers were not adjusted for other clinical parameters. Thus, the impacts of these markers on patient outcomes were substantially limited. Nonetheless, we believe that these results may help clinicians assess the overall status of hemodialysis patients since their levels could reflect physical performance. Finally, we could not determine the possible mechanisms underlying the association between low physical performance and high mortality. We speculate that chronic sustained inflammation might be an essential mediator that contributes to both phenomena (**Figure 3**). This hypothesis should be explored in further studies.

Conclusion

Our data suggest that poor physical performance, as assessed by GS and HS, was significantly associated with high all-cause mortality and cardiovascular diseases in hemodialysis patients. GS and HS seem to capture the function of different sets of skeletal muscles, neurological impairments, and malnutrition that develop in ESRD patients. Given that the measurements of GS and HS are relatively easy to perform, the combination of these two tests would provide clinicians opportunities for better patient assessment and individualized care.

Abbreviations

ESRD, end-stage renal disease

CKD, chronic kidney disease

GS, gait speed

HS, handgrip strength

K-MMSE, Korean version of the Mini-Mental State Examination

BDI, Beck Depression Inventory

KDQOL-SF, Kidney Disease Quality Of Life-Short Form

MMP, matrix metalloproteinase

TNF, tumor necrosis factor

MAMC, mid-arm muscle circumference

OR, odds ratio

CI, confidence interval

hs-CRP, high-sensitivity C-reactive protein

HR, hazard ratio

Declarations

Ethics approval and consent to participate

The study was conducted in accordance with the Declaration of Helsinki, and the Institutional Review Board of each participating center approved the study protocol (KHNMC IRB No. 2016-04-039). Informed consent was obtained from all patients.

Consent for publication

Not applicable.

Availability of data and materials

The datasets used and/or analyzed in the current study are available from the corresponding author on reasonable request.

Competing interests

We declare that we have no conflicts of interest.

Funding

This study was supported by a grant from Fresenius Medical Care, Korea. The funders supported the initiation and maintenance of K-cohort, and the measurements of plasma cytokine levels.

Acknowledgments

Not applicable.

Authors' contributions

YHL and JSK drafted the article and performed the analysis and interpretation of the data. SWJ, HSH, JYM, KHJ, SHL, DHY, GJK, DYL, and HJL were responsible for the analysis and interpretation of the work. YGK was responsible for the study concept and design and analysis and interpretation of the data. All authors have read and approved the manuscript.

References

1. Jin DC, Yun SR, Lee SW, Han SW, Kim W, Park J et al. Current characteristics of dialysis therapy in Korea: 2016 registry data focusing on diabetic patients. *Kidney Res Clin Pract.* 2018;37(1):20-9.
2. Saran R, Robinson B, Abbott KC, Agodoa LYC, Bragg-Gresham J, Balkrishnan R et al. US Renal Data System 2018 Annual Data Report: Epidemiology of Kidney Disease in the United States. *Am J Kidney Dis.* 2019;73(3S1):A7-A8.
3. Choi H, Kim M, Kim H, Pyo Lee J, Lee J, Tak Park J et al. Excess mortality among patients on dialysis: Comparison with the general population in Korea. *Kidney Res Clin Pract.* 2014;33(2):89-94.
4. Collins AJ, Ma JZ, Umen A, Keshaviah P. Urea index and other predictors of hemodialysis patient survival. *Am J Kidney Dis.* 1994;23(2):272-82.
5. Cozzolino M, Mangano M, Stucchi A, Ciceri P, Conte F, Galassi A. Cardiovascular disease in dialysis patients. *Nephrol Dial Transplant.* 2018;33(suppl_3):iii28-iii34.
6. Han SS, Park JY, Kang S, Kim KH, Ryu DR, Kim H et al. Dialysis Modality and Mortality in the Elderly: A Meta-Analysis. *Clin J Am Soc Nephrol.* 2015;10(6):983-93.
7. Liem YS, Wong JB, Hunink MG, de Charro FT, Winkelmayer WC. Comparison of hemodialysis and peritoneal dialysis survival in The Netherlands. *Kidney Int.* 2007;71(2):153-8.
8. Owen WF, Jr., Lew NL, Liu Y, Lowrie EG, Lazarus JM. The urea reduction ratio and serum albumin concentration as predictors of mortality in patients undergoing hemodialysis. *N Engl J Med.* 1993;329(14):1001-6.
9. Tong J, Liu M, Li H, Luo Z, Zhong X, Huang J et al. Mortality and Associated Risk Factors in Dialysis Patients with Cardiovascular Disease. *Kidney Blood Press Res.* 2016;41(4):479-87.
10. Vonesh EF, Snyder JJ, Foley RN, Collins AJ. The differential impact of risk factors on mortality in hemodialysis and peritoneal dialysis. *Kidney Int.* 2004;66(6):2389-401.
11. Santilli V, Bernetti A, Mangone M, Paoloni M. Clinical definition of sarcopenia. *Clin Cases Miner Bone Metab.* 2014;11(3):177-80.
12. Painter P, Marcus RL. Assessing physical function and physical activity in patients with CKD. *Clin J Am Soc Nephrol.* 2013;8(5):861-72.
13. Reese PP, Cappola AR, Shults J, Townsend RR, Gadegbeku CA, Anderson C et al. Physical performance and frailty in chronic kidney disease. *Am J Nephrol.* 2013;38(4):307-15.

14. Dodds RM, Syddall HE, Cooper R, Kuh D, Cooper C, Sayer AA. Global variation in grip strength: a systematic review and meta-analysis of normative data. *Age Ageing*. 2016;45(2):209-16.
15. Norman K, Stobaus N, Gonzalez MC, Schulzke JD, Pirlich M. Hand grip strength: outcome predictor and marker of nutritional status. *Clin Nutr*. 2011;30(2):135-42.
16. Roberts HC, Denison HJ, Martin HJ, Patel HP, Syddall H, Cooper C et al. A review of the measurement of grip strength in clinical and epidemiological studies: towards a standardised approach. *Age Ageing*. 2011;40(4):423-9.
17. Leal VO, Mafra D, Fouque D, Anjos LA. Use of handgrip strength in the assessment of the muscle function of chronic kidney disease patients on dialysis: a systematic review. *Nephrol Dial Transplant*. 2011;26(4):1354-60.
18. Amparo FC, Cordeiro AC, Carrero JJ, Cuppari L, Lindholm B, Amodeo C et al. Malnutrition-inflammation score is associated with handgrip strength in nondialysis-dependent chronic kidney disease patients. *J Ren Nutr*. 2013;23(4):283-7.
19. Roshanravan B, Robinson-Cohen C, Patel KV, Ayers E, Littman AJ, de Boer IH et al. Association between physical performance and all-cause mortality in CKD. *J Am Soc Nephrol*. 2013;24(5):822-30.
20. Isoyama N, Qureshi AR, Avesani CM, Lindholm B, Barany P, Heimbürger O et al. Comparative associations of muscle mass and muscle strength with mortality in dialysis patients. *Clin J Am Soc Nephrol*. 2014;9(10):1720-8.
21. Kutner NG, Zhang R, Huang Y, Painter P. Gait Speed and Mortality, Hospitalization, and Functional Status Change Among Hemodialysis Patients: A US Renal Data System Special Study. *Am J Kidney Dis*. 2015;66(2):297-304.
22. Vogt BP, Borges MCC, Goes CR, Caramori JCT. Handgrip strength is an independent predictor of all-cause mortality in maintenance dialysis patients. *Clin Nutr*. 2016;35(6):1429-33.
23. Kittiskulnam P, Chertow GM, Carrero JJ, Delgado C, Kaysen GA, Johansen KL. Sarcopenia and its individual criteria are associated, in part, with mortality among patients on hemodialysis. *Kidney Int*. 2017;92(1):238-47.
24. Mori K, Nishide K, Okuno S, Shoji T, Emoto M, Tsuda A et al. Impact of diabetes on sarcopenia and mortality in patients undergoing hemodialysis. *BMC Nephrol*. 2019;20(1):105.
25. Lee YH, Shin YS, Lee SY, Kim YG, Lee SH, Moon JY et al. Effects of online hemodiafiltration on anemia and nutritional status in chronic hemodialysis patients. *Kidney Res Clin Pract*. 2020;39(1):103-11.
26. Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. *J Chronic Dis*. 1987;40(5):373-83.
27. Liu J, Huang Z, Gilbertson DT, Foley RN, Collins AJ. An improved comorbidity index for outcome analyses among dialysis patients. *Kidney Int*. 2010;77(2):141-51.
28. Chen LK, Liu LK, Woo J, Assantachai P, Auyeung TW, Bahyah KS et al. Sarcopenia in Asia: consensus report of the Asian Working Group for Sarcopenia. *J Am Med Dir Assoc*. 2014;15(2):95-101.

29. Molloy DW, Standish TI. A guide to the standardized Mini-Mental State Examination. *Int Psychogeriatr*. 1997;9 Suppl 1:87-94; discussion 143-50.
30. Beck AT, Ward CH, Mendelson M, Mock J, Erbaugh J. An inventory for measuring depression. *Arch Gen Psychiatry*. 1961;4:561-71.
31. Park HJ, Kim S, Yong JS, Han SS, Yang DH, Meguro M et al. Reliability and validity of the Korean version of Kidney Disease Quality of Life instrument (KDQOL-SF). *Tohoku J Exp Med*. 2007;211(4):321-9.
32. Lee YH, Kim KP, Park SH, Kim DJ, Kim YG, Moon JY et al. Urinary chemokine C-X-C motif ligand 16 and endostatin as predictors of tubulointerstitial fibrosis in patients with advanced diabetic kidney disease. *Nephrol Dial Transplant*. 2019.
33. Nixon AC, Bampouras TM, Pendleton N, Woywodt A, Mitra S, Dhaygude A. Frailty and chronic kidney disease: current evidence and continuing uncertainties. *Clin Kidney J*. 2018;11(2):236-45.
34. Lin YL, Liou HH, Lai YH, Wang CH, Kuo CH, Chen SY et al. Decreased serum fatty acid binding protein 4 concentrations are associated with sarcopenia in chronic hemodialysis patients. *Clin Chim Acta*. 2018;485:113-8.
35. Kim JK, Kim SG, Oh JE, Lee YK, Noh JW, Kim HJ et al. Impact of sarcopenia on long-term mortality and cardiovascular events in patients undergoing hemodialysis. *Korean J Intern Med*. 2019;34(3):599-607.
36. Lin YL, Chen SY, Lai YH, Wang CH, Kuo CH, Liou HH et al. Angiotensin II receptor blockade is associated with preserved muscle strength in chronic hemodialysis patients. *BMC Nephrol*. 2019;20(1):54.
37. Zemp DD, Giannini O, Quadri P, de Bruin ED. Gait characteristics of CKD patients: a systematic review. *BMC Nephrol*. 2019;20(1):83.
38. Gomes Neto M, de Lacerda FFR, Lopes AA, Martinez BP, Saquetto MB. Intradialytic exercise training modalities on physical functioning and health-related quality of life in patients undergoing maintenance hemodialysis: systematic review and meta-analysis. *Clin Rehabil*. 2018;32(9):1189-202.
39. Young HML, March DS, Graham-Brown MPM, Jones AW, Curtis F, Grantham CS et al. Effects of intradialytic cycling exercise on exercise capacity, quality of life, physical function and cardiovascular measures in adult haemodialysis patients: a systematic review and meta-analysis. *Nephrol Dial Transplant*. 2018;33(8):1436-45.
40. Clarkson MJ, Bennett PN, Fraser SF, Warmington SA. Exercise interventions for improving objective physical function in patients with end-stage kidney disease on dialysis: a systematic review and meta-analysis. *Am J Physiol Renal Physiol*. 2019;316(5):F856-F72.
41. Ferrari F, Helal L, Dipp T, Soares D, Soldatelli A, Mills AL et al. Intradialytic training in patients with end-stage renal disease: a systematic review and meta-analysis of randomized clinical trials assessing the effects of five different training interventions. *J Nephrol*. 2019.
42. Pu J, Jiang Z, Wu W, Li L, Zhang L, Li Y et al. Efficacy and safety of intradialytic exercise in haemodialysis patients: a systematic review and meta-analysis. *BMJ Open*. 2019;9(1):e020633.

43. Salhab N, Karavetian M, Kooman J, Fiaccadori E, El Khoury CF. Effects of intradialytic aerobic exercise on hemodialysis patients: a systematic review and meta-analysis. *J Nephrol.* 2019;32(4):549-66.
44. Calella P, Hernandez-Sanchez S, Garofalo C, Ruiz JR, Carrero JJ, Bellizzi V. Exercise training in kidney transplant recipients: a systematic review. *J Nephrol.* 2019;32(4):567-79.
45. Ferrari F, Helal L, Dipp T, Soares D, Soldatelli A, Mills AL et al. Intradialytic training in patients with end-stage renal disease: a systematic review and meta-analysis of randomized clinical trials assessing the effects of five different training interventions. *J Nephrol.* 2020;33(2):251-66.
46. Koyun D, Nergizoglu G, Kir KM. Evaluation of the relationship between muscle mass and serum myostatin levels in chronic hemodialysis patients. *Saudi J Kidney Dis Transpl.* 2018;29(4):809-15.
47. Daugirdas JT. Second generation logarithmic estimates of single-pool variable volume Kt/V: an analysis of error. *J Am Soc Nephrol.* 1993;4(5):1205-13.
48. Hamasaki H. Lower Extremity Skeletal Muscle Mass, but Not Upper Extremity Skeletal Muscle Mass, Is Inversely Associated with Hospitalization in Patients with Type 2 Diabetes. *J Diabetes Res.* 2017;2017:2303467.
49. Harris-Love MO, Benson K, Leasure E, Adams B, McIntosh V. The Influence of Upper and Lower Extremity Strength on Performance-Based Sarcopenia Assessment Tests. *J Funct Morphol Kinesiol.* 2018;3(4).
50. Johansen KL, Delgado C, Kaysen GA, Chertow GM, Chiang J, Dalrymple LS et al. Frailty Among Patients Receiving Hemodialysis: Evolution of Components and Associations With Mortality. *J Gerontol A Biol Sci Med Sci.* 2019;74(3):380-6.
51. Sarrazin S, Adam E, Lyon M, Depontieu F, Motte V, Landolfi C et al. Endocan or endothelial cell specific molecule-1 (ESM-1): a potential novel endothelial cell marker and a new target for cancer therapy. *Biochim Biophys Acta.* 2006;1765(1):25-37.
52. Yilmaz MI, Siriopol D, Saglam M, Kurt YG, Unal HU, Eyiletten T et al. Plasma endocan levels associate with inflammation, vascular abnormalities, cardiovascular events, and survival in chronic kidney disease. *Kidney Int.* 2014;86(6):1213-20.
53. de Souza LV, Oliveira V, Laurindo AO, Huarachi DG, Nogueira PC, Feltran LS et al. Serum Endocan Levels Associated with Hypertension and Loss of Renal Function in Pediatric Patients after Two Years from Renal Transplant. *Int J Nephrol.* 2016;2016:2180765.
54. Lee YH, Kim JS, Kim SY, Kim YG, Moon JY, Jeong KH et al. Plasma endocan level and prognosis of immunoglobulin A nephropathy. *Kidney Res Clin Pract.* 2016;35(3):152-9.
55. Lee YH, Kim SY, Moon H, Seo JW, Kim DJ, Park SH et al. Endocan as a marker of microvascular inflammation in kidney transplant recipients. *Sci Rep.* 2019;9(1):1854.
56. Kose M, Emet S, Akpınar TS, Kocaaga M, Cakmak R, Akarsu M et al. Serum Endocan Level and the Severity of Coronary Artery Disease: A Pilot Study. *Angiology.* 2015;66(8):727-31.
57. Pauly D, Hamed S, Behnes M, Lepiorz D, Lang S, Akin I et al. Endothelial cell-specific molecule-1/endocan: Diagnostic and prognostic value in patients suffering from severe sepsis and septic

- shock. *J Crit Care*. 2016;31(1):68-75.
58. Muller-Quernheim J. MMPs are regulatory enzymes in pathways of inflammatory disorders, tissue injury, malignancies and remodelling of the lung. *Eur Respir J*. 2011;38(1):12-4.
59. Kazantseva MG, Hung NA, Highton J, Hessian PA. MMP expression in rheumatoid inflammation: the rs11568818 polymorphism is associated with MMP-7 expression at an extra-articular site. *Genes Immun*. 2013;14(3):162-9.
60. Vandenbroucke RE, Vanlaere I, Van Hauwermeiren F, Van Wonterghem E, Wilson C, Libert C. Pro-inflammatory effects of matrix metalloproteinase 7 in acute inflammation. *Mucosal Immunol*. 2014;7(3):579-88.
61. Sohar I, Laszlo A, Gaal K, Mechler F. Cysteine and metalloproteinase activities in serum of Duchenne muscular dystrophic genotypes. *Biol Chem Hoppe Seyler*. 1988;369 Suppl:277-9.

Tables

Table 1. Baseline characteristics and clinical parameters of enrolled patients according to gait speed and handgrip strength.

	Normal GS and HS (n=119)	Normal GS and low HS (n=80)	Low GS and normal HS (n=34)	Low GS and HS (n=44)	<i>p</i> value
Age (year)	58.6±14.3	61.5±11.1	63.7±10.3	68.6±12.0	<0.001 ^{c,e}
Sex (male, %)	75 (63.0)	61 (76.2)	19 (55.9)	28 (63.6)	0.118
BMI (kg/m ²)	23.2±4.2	22.5±3.3	24.5±4.5	22.1±3.2	0.024 ^e
Time on dialysis (year)	2.8 [0.8, 5.9]	3.3 [0.8, 7.8]	1.1 [0.3, 2.6]	1.4 [0.3, 4.8]	0.005 ^e
Previous cardiovascular events (n, %)	26 (21.8)	28 (35.0)	11 (32.4)	19 (43.2)	0.039 ^{a,c}
Diabetes mellitus (n, %)	55 (46.2)	44 (55.0)	23 (67.6)	31 (70.5)	0.017 ^{b,c}
Pre-HD SBP (mmHg)	141±20	142±25	143±19	140±21	0.949
Access type (n, %)					
Arteriovenous fistula	101 (84.9)	61 (76.2)	24 (70.6)	36 (81.8)	0.343
Arteriovenous graft	15 (12.6)	16 (20.0)	10 (29.4)	6 (13.6)	
Catheter	3 (2.5)	3 (3.8)	0 (0)	2 (4.5)	
Single-pool Kt/V	1.54±0.29	1.59±0.26	1.57±0.29	1.68±0.27	0.039 ^c
Hemoglobin (g/dL)	10.6±1.3	10.4±1.3	10.6±1.2	10.2±1.3	0.417
Albumin (g/dL)	3.9±0.3	3.9±0.3	3.8±0.4	3.7±0.3	0.002 ^{c,e}
Pre-HD BUN (mg/dL)	62.8±17.8	58.4±13.9	55.9±17.7	54.5±23.1	0.027 ^c
Pre-HD creatinine (mg/dL)	9.7±3.1	9.4±2.2	8.1±2.8	7.5±2.6	<0.001 ^{b,c,e}
Ca (mg/dL)	8.5±0.8	8.7±0.8	8.3±0.7	8.7±0.9	0.037 ^d
P (mg/dL)	5.0±1.4	4.7±1.2	4.7±1.4	4.4±1.6	0.153
Intact PTH (pg/mL)	190 [128, 302]	221 [119, 303]	185 [104, 370]	106 [58, 234]	0.060
Total CO ₂ (mEq/L)	22.5±3.0	23.3±3.1	22.6±2.9	23.3±2.9	0.246
β ₂ -microglobulin (mg/L)	25.2±8.6	24.4±7.4	21.4±7.3	25.1±9.3	0.142
Total cholesterol (mg/dL)	143±29	132±28	145±32	141±31	0.019 ^e
LDL cholesterol (mg/dL)	78±24	73±25	75±26	85±28	0.095
HDL cholesterol (mg/dL)	45±15	45±12	45±16	45±13	1.000
Gait speed* (m/s)	1.14±0.24	1.09±0.18	0.66±0.13	0.62±0.13	<0.001 ^{b,c,d,e}
Handgrip strength* (kg)					
Male	31.9±9.2	19.4±4.2	26.3±13.6	18.9±4.9	<0.001 ^{a,b,c,d,f}
Female	21.4±9.6	14.2±2.1	18.4±6.1	13.7±2.2	<0.001 ^{a,c}
MAMC [†] (cm)	23.3±3.4	22.5±4.4	22.3±2.5	21.6±3.5	0.074
Anti-hypertensive medication (n, %)					
Renin-angiotensin system blocker	67 (56.3)	42 (52.5)	23 (67.6)	25 (56.8)	0.524
Calcium channel blocker	74 (62.2)	44 (55.0)	21 (61.8)	30 (68.2)	0.523
β-blocker	46 (38.7)	30 (37.5)	19 (55.9)	20 (45.5)	0.250
HMG-CoA reductase inhibitor	51 (42.9)	31 (38.8)	21 (61.8)	27 (61.4)	0.022 ^{c,d,e}

Abbreviations: GS, gait speed; HS, handgrip strength; BMI, body mass index; HD, hemodialysis; CV, cardiovascular; SBP, systolic blood pressure; BUN, blood urea nitrogen; PTH, parathyroid hormone; LDL, low-density lipoprotein; HDL,

high-density lipoprotein; MAMC, mid-arm muscle circumference.

*Low GS was defined as a gait speed of less than 0.8 m/s, and low HS was defined as < 26 kg for men and < 18kg for women.

†MAMC was calculated by the following: MAMC = Midarm Circumference - (3.14163 X Triceps Skinfold Thickness / 10).

^a $p < 0.05$, Normal GS and HS vs. Normal GS and low HS; ^b $p < 0.05$, Normal GS and HS vs. Low GS and normal HS;

^c $p < 0.05$, Normal GS and HS vs. Low GS and HS; ^d $p < 0.05$, Normal GS and low HS vs. Low GS and normal HS; ^e $p < 0.05$, Normal GS and low HS vs. Low GS and HS.

Data are expressed as mean \pm standard deviation or the number of patients (percentage).

Table 2. Association between physical performance, comorbidity index, and quality of life.

	Normal GS and HS	Normal GS and low HS	Low GS and normal HS	Low GS and HS	<i>p</i> value
Charlson comorbidity scores*	4 [2, 4]	4 [3, 5]	5 [3, 5]	5 [4, 5]	<0.001 ^{a,b,c,e}
Liu comorbidity scores*	4 [3, 5]	4 [3, 6]	6 [4, 7]	6 [4, 7]	<0.001 ^{c,e}
K-MMSE [†]	28 [26, 29]	27 [24, 28]	27 [25, 30]	27 [23, 29]	0.030 ^c
BDI [†]	14 [7, 21]	13 [9, 20]	17 [6, 25]	16 [11, 28]	0.122
KD-QOL [†]					
Physical components					
Physical functioning	85 [65, 95]	77 [50, 90]	60 [23, 80]	40 [25, 65]	<0.001 ^{b,c,d,e}
Pain	73 [58, 100]	76 [55, 100]	78 [45, 90]	55 [45, 80]	0.050 ^c
General health	35 [25, 50]	40 [25, 57]	35 [21, 49]	25 [15, 35]	0.003 ^{c,e}
Energy/fatigue	45 [35, 59]	50 [39, 55]	50 [40, 55]	40 [20, 50]	0.049 ^c
Mental components					
Cognitive function	87 [80, 100]	87 [67, 100]	80 [60, 93]	73 [60, 93]	0.007 ^{b,c}
Sleep	60 [50, 73]	60 [53, 75]	58 [46, 65]	58 [43, 65]	0.367
Emotional well-being	60 [45, 72]	60 [52, 76]	60 [52, 68]	52 [40, 64]	0.089
Social components					
Work status	0 [0, 50]	0 [0, 50]	0 [0, 50]	0 [0, 50]	0.170
Quality of social interaction	67 [60, 80]	67 [60, 87]	67 [53, 80]	67 [60, 80]	0.772
Social support	67 [67, 100]	67 [67, 100]	67 [67, 100]	67 [50, 100]	0.902
Social function	75 [63, 100]	75 [50, 100]	75 [38, 100]	63 [50, 75]	0.021 ^c

Abbreviations: GS, gait speed; HS, handgrip strength; K-MMSE, Korean-version of mini-mental state exam; BDI, Beck's depression inventory; KD-QOL, kidney disease quality of life.

*Charlson comorbidity score and Liu comorbidity score are adapted from reference 25 and 26.

†The detailed information regarding the list of questionnaire can be checked in reference 28, 29, and 30.

^a $p < 0.05$, Normal GS and HS vs. Normal GS and low HS; ^b $p < 0.05$, Normal GS and HS vs. Low GS and normal HS;

^c $p < 0.05$, Normal GS and HS vs. Low GS and HS; ^d $p < 0.05$, Normal GS and low HS vs. Low GS and normal HS; ^e $p < 0.05$, Normal GS and low HS vs. Low GS and HS.

Table 3. Logistic regression on the determinant factors of low gait speed and low handgrip strength.

	Low gait speed				Low handgrip strength			
	Univariate		Multivariate		Univariate		Multivariate	
	OR (95% CI)	<i>p</i> value	OR (95% CI)	<i>p</i> value	OR (95% CI)	<i>p</i> value	OR (95% CI)	<i>p</i> value
Age (per 10 years increment)	1.61 (1.28-2.01)	<0.001	1.51 (1.20-1.91)	0.001	1.32 (1.10-1.59)	0.004	1.02 (1.00-1.4)	0.026
Male (vs. female)	1.42 (0.83-2.45)	0.202			0.63 (0.38-1.04)	0.072		
BMI (per 1 kg/m ² increment)	1.01 (0.95-1.08)	0.702			0.92 (0.86-0.98)	0.014	0.92 (0.86-0.99)	0.022
Time on dialysis (per 1 year increment)	0.91 (0.86-0.98)	0.008	0.94 (0.88-1.01)	0.081	1.02 (0.97-1.06)	0.451		
Diabetes (vs. absent)	2.27 (1.30-3.96)	0.004	2.12 (1.16-43.86)	0.014	1.47 (0.91-2.38)	0.114		
Previous cardiovascular event (vs. absent)	1.68 (0.97-2.92)	0.066			1.91 (1.14-3.21)	0.014	1.73 (1.02-2.95)	0.043
Albumin (per 1 g/dL decrement)	4.90 (2.03-11.83)	<0.001	3.37 (1.32-8.62)	0.011	1.69 (0.79-3.62)	0.177		

Abbreviations; OR, odds ratio; CI, confidence interval; BMI, body mass index; HD, hemodialysis; SBP, systolic blood pressure.

Table 4. Incidence and hazard ratios of cumulative composite event rate based on the physical performance.

	No. of events (%)	<i>p</i> for interaction	Adjustment model 1* (HR [95% CI])	<i>p</i> value	Adjustment model 2* (HR [95% CI])	<i>p</i> value
Cumulative composite event rate [†]						
Normal GS and HS	14 (11.8)	0.019	Reference	-	Reference	-
Normal GS and low HS	12 (15.0)		1.08 (0.49-2.39)	0.843	1.15 (0.52-2.54)	0.737
Low GS and normal HS	6 (17.6)		2.38 (0.86-6.53)	0.084	1.92 (0.69-5.31)	0.211
Low GS and HS	13 (29.5)		2.72 (1.14-6.46)	0.024	2.30 (1.02-5.21)	0.045

* Model 1 was adjusted by age, sex, previous history of cardiovascular disease, and serum albumin levels. Model 2 was adjusted by Charlson comorbidity score.

[†] Cumulative incidence of all-cause mortality and cardiovascular events

Abbreviations: HR, hazard ratios; CI, confidence interval; GS, gait speed; HS, handgrip strength.

Figures




Figure 1

A flowchart of the study participant selection Abbreviations: GS, gait speed; HS, handgrip strength.




Figure 2

Correlation between gait speed and handgrip strength. Shown is the scatter plot displaying the relationship between gait speed and handgrip strength. Although these two parameters were significantly correlated with each other, the correlation was very weak ($R^2 = 0.070$, $p < 0.001$).




Figure 3

Levels of various plasma inflammatory markers in hemodialysis patients according to physical performance. Among the plasma inflammatory markers measured by multiplex enzyme-linked immunosorbent assay, the levels of (A) endocan and (B) MMP-7 were significantly higher in patients with low GS and HS than in those with normal GS and HS. The levels of (C) TNF- α , (D) IL-6, and (E) hs-CRP were not different among the groups. Abbreviations: GS, gait speed; HS, handgrip strength; MMP, matrix metalloproteinase; TNF, tumor necrosis factor; hs-CRP, high-sensitivity C-reactive protein.




Figure 4

Cumulative event rate of all-cause mortality and cardiovascular events in hemodialysis patients according gait speed and handgrip strength. Patients with low GS and HS showed the highest cumulative composite event rate ($p = 0.004$ for overall trends). Abbreviations: GS, gait speed; HS, handgrip strength.




Figure 5

Adjusted hazard ratios of the cumulative composite event rate based on age and physical performance. Elderly hemodialysis patients with low GS and HS exhibited a significantly higher risk of major adverse events (adjusted HR of 5.76, 95% CI of 1.78 – 18.62; $p = 0.012$), while physical performance was not associated with composite outcomes in patients under 65 years. The outcome was defined as the composite of all-cause mortality and/or major cardiovascular events, and the composite incidence rate of hemodialysis under 65 years with normal GS and HS was set as the reference. Dots and I bars indicate adjusted HR and 95% CI, respectively. Abbreviations: GS, gait speed; HS, handgrip strength; HR, hazard ratio; CI, confidence interval.